BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » mesenchymal stem cells » Page 2

Key Dates in the Discovery of Mesenchymal Stem Cells (MSCs)

August 25, 2017 By Cade Hildreth (CEO) Leave a Comment

nutristem | Top 5 Reasons to Use Biological Industries’ NutriStem® for Isolation and Growth of hMSCs

Mesenchymal stem cells (MSCs) have inspired a great deal of activity as a novel therapeutic approach. Presently, MSC-based clinical trials are being conducted for a variety of disease conditions, with many trials demonstrating safety and efficacy.

Clinical utility of MSCs can be attributed to four key biological properties:

  1. Their potential to migrate to sites of inflammation caused by tissue injury when injected intravenously
  2. Their potential to differentiate into different cell types
  3. Their potential to release different bioactive molecules that can stimulate the recovery of injured cells
  4. Their ability to modulate inflammation and accomplish immunomodulatory functions

Currently, several hundred MSC clinical trials are in progress across different parts of the world, including within the U.S. European Union (EU), China, Middle East, and South Korea. Among these clinical trials, approximately one-third are exploiting MSCs for various disease indications. Unfortunately, only a small number of clinical trials using MSCs have reached Phase III, indicating that the therapeutic potential for MSCs has yet to be realized.

One of the major bottlenecks to the industry is how to manufacture clinical-grade MSCs on a commercial scale, which Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) is aiming to solve.

To fully understand the cell type and its evolution over time, this post considers key dates in the discovery of mesenchymal stem cells (MSCs). [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: history, mesenchymal stem cells

Longeveron Begins Enrollment of Second Cohort of Phase 1 Alzheimer’s Disease Trial

May 10, 2017 By Cade Hildreth (CEO) Leave a Comment

Longeveron Enters Phase 1 Alzheimer's Trial

MIAMI, May 10, 2017 — Longeveron companyLongeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.

The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.

[Read more…]

Filed Under: MSCs, Press Releases, Stem Cells Tagged With: allogeneic, Alzheimer's, LMSCs, Longeveron, mesenchymal stem cells

Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost

November 11, 2016 By Cade Hildreth (CEO) Leave a Comment

Cynata - MSC Manufacturing

For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.

MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: cell therapy, cynata therapeutics, iPSC, market news, mesenchymal stem cells

Current Landscape for Stem Cell Clinical Trials

November 11, 2016 By Cade Hildreth (CEO) Leave a Comment

Landscape for Stem Cell Clinical Trials

To understand the growing market potential for stem cell therapies, it is critical to consider the current landscape for stem cell clinical trials.

ClinicalTrials.govThere are 5561 clinical trials found when the term “stem cells” is searched on ClinicalTrials.gov, indicating that there are now thousands of stem cell trials underway worldwide. (Search executed November 7, 2016.)

ClinicalTrials.gov is the global registry of publicly and privately supported clinical studies involving human patients. While not a comprehensive resource, it contains approximately three-quarters of registered cell therapy trials worldwide.

Below is a map showing the location of current stem cell clinical trials.

Map of Stem Cell Clinical Trials, by Geographical Region

Map of Stem Cell Clinical Trials

“Hotspots” for Stem Cell Clinical Trial Activity

Clearly, North America (3057 trials) and Europe (1288 trials) are “hotspots” for stem cell clinical trial activity.

Among the North American trials, nearly all of them of them are occurring in the United States (2935).  [Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Stem Cell News, Stem Cells Tagged With: clinical trial, mesenchymal stem cells

Analyzing the Mesenchymal Stem Cell (MSC) Market Using Social Analytics

October 25, 2016 By Cade Hildreth (CEO) 1 Comment

Top 10 Hashtags Related to the Term “Mesenchymal” on Twitter

Twitter Metrics for BioInformant - @StemCellMartketOne of the ways to use market intelligence to analyze trends within the mesenchymal stem cell (MSC) market is to assess how the cell type is being discussed on leading social media platforms, such as Twitter.

Twitter.com is one of the most widely used social media platforms today. It has with 316 million monthly active users and 500 million Tweets sent per day, according to Twitter’s company statistics. 

It is also the 9th most visited website in the world, an impressive accomplishment.

Social Analytics Reveal Key Trends about Mesenchymal Stem Cell (MSC) Research

The figure below shows a hashtag map for the term “#mesenchymal.” It was produced using the  social analytics platform Hashtagify.me.

The linked topics shown as spokes in this figure represent the top hashtags that are used together with the hashtag “#mesenchymal” on Twitter.
[Read more…]

Filed Under: MSCs, Stem Cells Tagged With: mesenchymal stem cells, social analytics, stem cells, twitter

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.